REYATAZ CAPSULE 150 mg Singapore - inglese - HSA (Health Sciences Authority)

reyataz capsule 150 mg

bristol-myers squibb (singapore) pte. ltd. - atazanavir sulfate 170.83 mg eqv atazanavir - capsule - 150 mg - atazanavir sulfate 170.83 mg eqv atazanavir 150 mg

VFEND FILM-COATED TABLET 50 mg Singapore - inglese - HSA (Health Sciences Authority)

vfend film-coated tablet 50 mg

pfizer private limited - voriconazole - tablet, film coated - 50 mg - voriconazole 50 mg

PREZISTA™ TABLET 150MG Singapore - inglese - HSA (Health Sciences Authority)

prezista™ tablet 150mg

johnson & johnson international (singapore) pte ltd - darunavir ethanolate 162.62 mg eqv darunavir - tablet, film coated - 150mg - darunavir ethanolate 162.62 mg eqv darunavir 150mg

Tybost Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

tybost

gilead sciences (nz) - cobicistat 150mg;  ;  ;   - film coated tablet - 150 mg - active: cobicistat 150mg       excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry orange 85f93642 - tybost is indicated as a pharmacokinetic enhancer of appropriate hiv-1 protease inhibitors in adults

SUSTIVA 50MG CAPSULE Canada - inglese - Health Canada

sustiva 50mg capsule

bristol-myers squibb canada - efavirenz - capsule - 50mg - efavirenz 50mg - nonnucleoside reverse transcriptase inhibitors

KALETRA TABLETS lopinavir 200mg and ritonavir 50mg tablets bottle Australia - inglese - Department of Health (Therapeutic Goods Administration)

kaletra tablets lopinavir 200mg and ritonavir 50mg tablets bottle

abbvie pty ltd - lopinavir, quantity: 200 mg; ritonavir, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium stearylfumarate; macrogol 3350; hyprolose; macrogol 400; colloidal anhydrous silica; polysorbate 80; purified talc; copovidone; titanium dioxide; iron oxide yellow; hypromellose; sorbitan monolaurate - kaletra is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older. this indication is based on the analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled clinical studies (see clinical trials).